Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Next Previous
Trial Profile

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Goserelin (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Carcinoma; Salivary gland cancer
  • Focus Therapeutic Use

Most Recent Events

  • 11 Oct 2024 Planned End Date changed from 1 Sep 2024 to 1 Oct 2025.
  • 11 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
  • 04 Sep 2024 Planned End Date changed from 1 Jul 2024 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top